Autolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia

MT Newswires Live

04/26

Autolus Therapeutics (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.

The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.

Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.

Shares of Autolus were down 4.3% in recent trading.

Price: 1.34, Change: -0.06, Percent Change: -4.29

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2530157840"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530157840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530157840?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-26 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530157840","market":"sg","top_or_hot":-1,"title":"Autolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia","media":"MT Newswires Live","content":"<html><body><p> Autolus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.</p><p>The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.</p><p>The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.</p><p>Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.</p><p>Shares of Autolus were down 4.3% in recent trading.</p><p>Price: 1.34, Change: -0.06, Percent Change: -4.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Autolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAutolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-26 00:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Autolus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.</p><p>The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.</p><p>The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.</p><p>Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.</p><p>Shares of Autolus were down 4.3% in recent trading.</p><p>Price: 1.34, Change: -0.06, Percent Change: -4.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUTL","symbol_name":"Autolus Therapeutics PLC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2530157840","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530157840","pubTimestamp":1745598737,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Autolus Therapeutics  said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.Shares of Autolus were down 4.3% in recent trading.Price: 1.34, Change: -0.06, Percent Change: -4.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUTL":"Autolus Therapeutics PLC","BK4139":"生物科技"},"translate_title":"Autolus获得Aucatzyl治疗复发性白血病的有条件上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":0.9},"content_text":"Autolus Therapeutics (AUTL) said Friday that the UK Medicines and Healthcare products Regulatory Agency granted conditional marketing authorization for Aucatzyl to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.The authorization is based on results from the Felix study, an open-label, multicenter, single-arm trial in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to the company.The biopharmaceutical company said it submitted obecabtagene autoleucel, an autologous CD19 CAR T cell therapy with a proprietary CD19 CAR, for appraisal by the National Institute for Health and Care Excellence in Q4 2024.Autolus is currently working with NICE and the NHS to potentially enable access for eligible patients in England.Shares of Autolus were down 4.3% in recent trading.Price: 1.34, Change: -0.06, Percent Change: -4.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}